The enzyme dipeptidyl peptidase 4 (DPP4) can rapidly degrade glucagon-like peptide 1 (GLP-1), which increases insulin secretion and improves insulin sensitivity, making it a promising therapeutic target for type 2 diabetes [223]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.